Roche has moved to end two Huntington’s disease antisense programs with Ionis, citing data-driven decisions after key efficacy setbacks and new stopping information. The Phase 2 GENERATION HD2 study of tominersen did not meet its primary efficacy objective, and Roche also stopped the RG6496 trial after new data emerged from parallel animal work. Roche said the decision reflects the “totality of data” and called the outcome “deeply disappointing,” while noting the failures occurred alongside other company events. Ionis said earlier that its AstraZeneca-partnered Wainua (eplontersen) failed Phase 3 CARDIO-TTRansform in transthyretin amyloidosis cardiomyopathy, further compounding the sector’s antisense challenges. Together, the moves underscore how timing and program-level risk can shift rapidly in late-stage neurodegeneration and RNA-targeted therapeutics—especially when efficacy signals fail to translate into clinical endpoints.